Associated Papers
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC.
Shiller M et al.
Frontiers in Oncology, 2024
39703851 (PubMed )
Supplement: DataSheet2.xlsx › Supplemental_data
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee JK et al.
Npj Precision Oncology, 2022
36494601 (PubMed )
Supplement: 41698_2022_334_MOESM1_ESM.pdf
Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer.
Marbun VMG et al.
Plos One, 2022
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH et al.
Translational Lung Cancer Research, 2020
Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L et al.
Lung Cancer (amsterdam, Netherlands), 2019
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.
Van Allen EM et al.
Nature Medicine, 2014
24836576 (PubMed )
Supplement: NIHMS531666-supplement-2.pdf
Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
Takano S et al.
Plos One, 2014
STK11 p.F354L Germline Mutation in a Case of Multiple Gastrointestinal Tumors.
Kojima Y et al.
Case Reports in Gastroenterology, 0
Select a paper to view details